Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Alefacept Stories

2013-09-23 10:22:14

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby M.D., Ph.D. from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology. Alefacept, an engineered fusion protein targeting a surface molecule, CD2, found on T-lymphocytes, was the first...

2012-12-06 08:26:36

HORSHAM, Pa. and LEIDEN, Netherlands, Dec. 6, 2012 /PRNewswire/ -- Janssen Biotech, Inc. and Janssen Biologics B.V. announced today the submission of a supplemental Biologics License Application (sBLA) to the United States Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) requesting approval of STELARA(®) (ustekinumab) for the treatment of adult patients with active psoriatic arthritis. It is estimated that more than two million people in...

2012-10-29 03:20:51

BEERSE, Belgium, October 29, 2012 /PRNewswire/ -- Pledge Your Support Today to Help Drive Much-needed Change for People With Psoriasis Promising interim results from the Psoriasis Mandate have been released today to mark World Psoriasis Day [http://www.worldpsoriasisday.com ]. To date 1145 people across 40 European countries have pledged their support for five basic rights of people with psoriasis, but experts are urging...

2012-06-06 02:25:36

VERONA, Italy, June 6, 2012 /PRNewswire/ -- New efficacy and safety data from the Phase 3 PHOENIX 1 study, one of two pivotal registration trials, showed that maintenance treatment with STELARA® (ustekinumab) for up to five years resulted in consistent, significant clinical response in adults with moderate to severe plaque psoriasis. Among responders receiving STELARA 45 mg or 90 mg and randomized to continue maintenance therapy through five years, 79 and 81 percent of patients,...

2010-08-09 07:00:00

CHICAGO, Aug. 9 /PRNewswire/ -- New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a...

2010-01-19 12:06:30

Findings from a cost model suggest that expenses for systemic psoriasis therapy appear to be increasing at a faster rate than inflation, and newer biologically derived treatments are more expensive than traditional systemic therapies, according to a report in the January issue of Archives of Dermatology, one of the JAMA/Archives journals. Psoriasis is a chronic autoimmune disease that affects an estimated 4.5 million to 7.5 million Americans, costing the health care industry approximately...

2009-07-08 14:00:25

Transplant patients rely on drugs to prevent graft rejection, but at the cost of serious side effects. The class of immunosuppressive drugs known as calcineurin inhibitors (examples are cyclosporine and tacrolimus) can damage patients' kidneys and lead to high blood pressure, among other problems.A combination of treatments can effectively replace calcineurin inhibitors in preventing graft rejection when kidney transplants are performed on monkeys, scientists at the Emory Transplant Center...

2009-01-22 07:16:00

First and Only Biologic Approved with Infrequent, Every Twelve-Week Maintenance Dosing BEERSE, Belgium, Jan. 22 /PRNewswire/ -- Janssen-Cilag announced today that STELARA(TM) (ustekinumab), the first in a new class of biologics, has been approved by the European Commission for use across Europe. The approved indication of ustekinumab is for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other...